Recent Updates
Recently added Catalysts
NAUT Positive Sentiment

Announcing the Iterative Mapping Early Access Program!

Key Takeaway: Nautilus Biotechnology is launching the Iterative Mapping Early Access Program in January 2026, allowing select researchers to generate single-molecule proteomic data. The program will initially offer the Nautilus Tau Proteoforms assay, focusing on tau proteoform biology, which is critical for developing biomarkers and drug targets for neurodegenerative diseases. Participants will receive support from Nautilus in designing and analyzing their experiments.
Price reaction · baseline $2.22 (2026-01-07 close) · hit pre-market · clean, no other NAUT news in the window
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Early access to innovative single-molecule proteomic data.
  • Exclusive offerings for researchers in neurodegenerative disease studies.
  • Collaboration with Nautilus for optimized experiment design and analysis.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~29 mo
Minimal dilution risk
Lead asset
MDMA
Phase 2 · Post-Traumatic Stress Disorder

Full Press Release Details

Nautilus and our Platform
Nautilus Biotechnology
January 8, 2026
Starting in January 2026, the Nautilus Iterative Mapping Early Access Program enables you to be one of the first to generate single-molecule proteomic data using Nautilus’ single-molecule Iterative Mapping approach. The program will give you exclusive, early access to Iterative Mapping first as a fee-for-service offering through Nautilus Proteomics Analysis Services followed by a small number of instrument placements ahead of full launch in late 2026. All projects accepted into the program are run in coordination with Nautilus. We will help you design, run, and analyze your experiments ensuring you get the most out of your Iterative Mapping data.
Participants will be part of a limited group of researchers with early access to Iterative Mapping. Our first offering through the program is the Nautilus Tau Proteoforms assay, which enables exploration of critical aspects of tau proteoform biology. Tau proteoforms are not accessible with existing proteomics methods and may be key to developing the next generation of biomarkers and drug targets for neurodegenerative diseases. The program will expand with additional offerings in 2026.
If you’re interested in the Nautilus Tau Proteoforms assay, would like to use Iterative Mapping for a different application, or simply wish to stay informed about new capabilities, please fill out the form on the Iterative Mapping Early Access Program webpage.
Share this Article
Stay up-to-date on all things Nautilus
World-class articles, delivered weekly
MORE ARTICLES
Nautilus: Driving a revolution in proteomic analysis
New protein sequencing technology from Nautilus is unlocking the proteome and igniting a proteomics revolution.
Read more
A brief introduction to PrISM – The theoretical framework underpinning the Nautilus platform
Learn about Protein Identification by Short epitope Mapping (PrISM) - The theoretical framework underpinning the Nautilus Platform.
Read more
Nautilus: Driving a revolution in proteomic analysis (Part 2)
We give you an inside view on how cross-disciplinary thinking and collaboration will propel us into a proteomics-powered future.
Read more
Stay up-to-date on all things Nautilus

Subscribe to our Newsletter

Frequently Asked Questions

What is the Nautilus Iterative Mapping Early Access Program?

It allows select researchers to generate single-molecule proteomic data starting January 2026.

What is the first offering in the program?

The first offering is the Nautilus Tau Proteoforms assay, focusing on tau proteoform biology.

How can researchers participate in the program?

Interested researchers can fill out a form on the Iterative Mapping Early Access Program webpage.

What support will Nautilus provide to participants?

Nautilus will assist in designing, running, and analyzing experiments for participants.

When will the full launch of the program occur?

The full launch of the program is expected in late 2026.

Last updated: Jan 8, 2026